Medical Facilities (DR) Q3 2024 earnings summary

Executive summary

• Q3 saw increased surgical case volumes, a net decrease in operating expenses, and significant capital returned to shareholders.

• Full forgiveness of all outstanding PPP loans resulted in recognition of $11.4 million in government stimulus income.

• Facility service revenue rose 0.2% to $103.6 million in Q3 2024 compared to Q3 2023, excluding divested centers.

• Surgical case volumes increased 3.1% year-over-year.

Financial highlights

• Total revenue and other income rose by $11.6 million (11.2%) to $115 million, driven by government stimulus income.

• Net income for Q3 2024 was $17.4 million, up 263.4% from $4.8 million in Q3 2023.

• EBITDA for Q3 2024 was $19.1 million, up 8.3% year-over-year, excluding government stimulus and non-cash charges.

• Basic and diluted EPS for Q3 2024 were $0.30, compared to a loss of $0.01 in Q3 2023.

• Operating expenses declined 1.1% to $90 million, with lower drugs and supplies costs offsetting higher salaries and G&A.

Outlook and guidance

• Management highlighted ongoing capital returns and operational improvements, with no explicit forward guidance provided.

• Forward-looking statements highlight risks from regulatory changes, competition, technology, and economic conditions.